Neuronanomedicine

描述(申请人提供)：神经医学是一个新的研究领域，其定义是开发和转化纳米技术，用于诊断和治疗神经系统的退行性、炎症性、感染性、血管、成瘾性、行为和代谢障碍。这一研究学科是跨学科的，还处于初级阶段。需要克服障碍才能实现成功，以改善已知的血脑屏障限制、纳米毒物、低效的药物靶向病变脑区和到达特定的神经亚细胞隔室。这些都对该领域构成了重大挑战。为了促进成功的研究成果，我们计划将从事神经肿瘤医学的不同背景的科学家聚集在一起，提出有助于定义该领域的研究结果，同时也为受训人员提供直接参与当前和未来讨论的机会。美国纳米医学学会(ASNM)通过将2013年会议的重点放在神经肿瘤医学的多方面学科上，发挥了领导作用。ASNM处于很好的地位来承担这一角色，因为自2008年成立以来，该协会的目标一直停留在纳米技术的临床翻译上。这些目标将是 在公开论坛讨论中促进，包括但不限于生物伦理、安全和毒性、知识产权和产品商业化。这次会议的一个主要焦点是 在将早期职业研究人员带入翻译神经肿瘤医学领域方面。ASNM对快速翻译方法的创新和实用性的强调与会议的目标一致，即合并不同的学科和方法，以促进从产品开发到实验室和动物试验，并最终到人类临床试验的协作研究。这项提案由经验丰富的内科科学家霍华德·詹德尔曼博士领导，利用了经验丰富、纪律严明的董事会。总体而言，对神经系统的关注代表着ASNM领导层的演变和会议方向的进一步改变。它将使该领域的新指令能够跟上纳米技术研究范围的需求。

DESCRIPTION (provided by applicant): Neuronanomedicine is a new research field defined as the development and translation of nanotechnology for diagnosis and treatment of degenerative, inflammatory, infectious, vascular, addictive, behavioral and metabolic disorders of the nervous system. The research discipline is interdisciplinary and in its infancy. Hurdles need be overcome for success to be realized that improve known blood brain barrier restrictions, nanotoxicologies, inefficient drug targeting to diseased brain regions and in reaching specific neural subcellular compartments. These all pose significant challenges to the field. To facilitate successful research outcomes we plan to bring together scientists from divergent backgrounds engaged in neuronanomedicine to present research findings that will help define the field while also facilitating opportunities for trainees to directly engage in currnt and future discussions. The American Society for Nanomedicine (ASNM) has taken a leadership role by focusing its 2013 meeting to the multifaceted discipline of neuronanomedicine. The ASNM is well positioned to assume this role as the society's goals since its 2008 inception has rested in clinical translation of nanotechnologies. Such goals will be fostered in an open forum discussion that will include, but is not limited to, bioethics, safety an toxicity, intellectual property, and product commercialization. A major focus for the conference is in bringing early career investigators into the field of translational neuronanomedicine. ASNM's emphasis on innovation and practicality of approaches for speedy translation parallels the conference goals on merging divergent disciplines and approaches to facilitate collaborative research from product development to laboratory and animal testing and ultimately to human clinical trials. The proposal while led by an experienced physician-scientist, Dr. Howard Gendelman, takes advantage of a highly seasoned broad-disciplined board. Overall, the focus on the nervous system represents an evolution of ASNM leadership and a further change in direction for the meeting. It will enable new directives in the field to keep abreast with needs an research scope in nanotechnology.